Oct 2026· Journal of Neurological Sciences· Vol 491, pp.
126236
· 0 citations· 93 references
Medicine
TL;DR
Current evidence supports a shift from fixed delay rules toward individualized anticoagulation strategies, and clinical decision-making should integrate stroke severity, neuroimaging findings, and individual thromboembolic and bleeding risks.
Abstract
Atrial fibrillation (AF) is a major risk factor for acute ischemic stroke (AIS), and oral anticoagulation is the cornerstone of secondary prevention. The optimal timing of anticoagulation initiation remains controversial because of the need to balance the risks of early ischemic recurrence and hemorrhagic transformation. Recent randomized controlled trials and meta-analyses indicate that early initiation of direct oral anticoagulants (DOACs) is generally safe in appropriately selected patients and may reduce recurrent ischemic events without increasing the risk of symptomatic intracranial hemorrhage. However, evidence remains limited in patients with severe stroke, hemorrhagic transformation, large infarcts, or recent reperfusion therapy, in whom the timing of anticoagulation should be individualized according to clinical and neuroimaging characteristics. The 2026 AHA/ASA guideline considers early oral anticoagulation reasonable in carefully selected patients with AIS and AF, particularly those with milder stroke severity, without specifying a uniform initiation window. Clinical decision-making should integrate stroke severity, neuroimaging findings, and individual thromboembolic and bleeding risks. Overall, current evidence supports a shift from fixed delay rules toward individualized anticoagulation strategies.
Secondary stroke prevention in patients with atrial fibrillation (AF) who experience an ischemic stroke (IS) despite oral anticoagulation remains challenging, and strategies have focused on antithrombotic optimization or left atrial appendage occlusion. Adjunctive statin therapy might reduce early vascular risk and...
G. Merlino, R. Ornello, L. D'Anna et al.· Therapeutic Advances in Neur...· 0 citations
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice and represents a major global health burden due to its association with ischemic stroke, systemic thromboembolism, heart failure, hospitalization, and increased mortality. The prevalence of AF continues to rise bec...
A. Sinani· INTERNATIONAL CONGRESS FROM...· 0 citations
BACKGROUND
Optimal antithrombotic therapy for ischemic stroke due to symptomatic large-artery atherosclerosis in patients with atrial fibrillation remains uncertain. We describe real-world prescribing patterns and outcomes across antithrombotic regimens.
METHODS
We retrospectively analyzed consecutive patients with a...
Ghada A. Mohamed, A. de Havenon, Renee' H. Martin et al.· Journal of the American Hear...· 0 citations
BACKGROUND AND OBJECTIVES
Early rhythm control reduces cardiovascular events in patients with atrial fibrillation (AF); however, its effectiveness in the setting of acute ischemic stroke remains uncertain. We aimed to examine whether early rhythm control after acute ischemic stroke is associated with a lower risk of re...
Shuhei Egashira, Kosuke Inoue, Masatoshi Koga et al.· Neurology· 0 citations
This review summarizes acute-phase treatment for minor ischemic stroke, focusing on the latest evidence for reperfusion therapy and acute antithrombotic treatment. In patients with large vessel occlusion, the benefit of mechanical thrombectomy is not established and the risk of hemorrhage exists; therefore, indications...